TULSA Effective in Controlling Prostate Cancer Long-Term
WASHINGTON — Results from a long-term follow-up of the pivotal TACT trial showed that MRI-guided transurethral ultrasound ablation (TULSA) was effective and durable in men with localized prostate cancer. The median prostate-specific antigen (PSA) level at 5 years was 0.63 ng/mL — a 90% reduction from the median PSA at baseline, reported Scott Eggener, MD, […]
Deaths From PSA-Detected Prostate Cancer Low at 15 Years, No Matter the Treatment
For prostate cancers detected by screening, cancer-specific mortality was low at 15-year follow-up regardless of whether patients underwent active monitoring, prostatectomy, or radiotherapy, results from the phase III randomized ProtecT study showed. Among over 1,600 men from the U.K. with prostate cancers detected by a prostate-specific antigen (PSA) test, death from their malignancy occurred in […]
Durable Remissions in CLL With Fixed-Duration Triplet at 4 Years
Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL) were presented at the American Society of Clinical Oncology annual meeting. In this exclusive MedPage Today video, Kerry Rogers, MD, of the Ohio State University Comprehensive Cancer Center in Columbus, discusses the […]
Study Confirms Declining Mammography Rates in Breast Cancer Survivors
Rates of follow-up mammography among breast cancer survivors declined significantly during the last decade, particularly among younger women, an analysis of health claims data showed. Rates of annual mammography decreased from 74.1% in 2004 to 67.1% in 2016, with all of the decline occurring from 2009 to 2016. Among breast cancer survivors ages 40 to […]